prnewswire.com
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved ... - PR Newswire
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care about, including after prior biologic failure.
It notes safety findings and regulatory approvals relevant to treatment access.
Adults with Crohn’s disease (including those with prior biologic failure), patients considering biologic therapy, clinicians treating IBD, and researchers tracking IL‑23 therapies.
What To Know
Lilly announced two-year results from the VIVID-2 open-label extension showing sustained clinical remission and endoscopic response with Omvoh (mirikizumab-mrkz) in adults with moderately to severely active Crohn’s disease.
The release summarizes observed-case and modified non-responder imputation analyses, safety findings over the second year, regulatory approvals and ongoing trials, and states data will be presented at Crohn’s and Colitis Congress.
This is a company press release summarizing results from the VIVID program and an open‑label extension; full study data and peer‑reviewed publications or conference slides will give more detail on study methods, patient numbers, and statistical analyses.
Reported outcomes include both observed‑case and modified non‑responder imputation analyses, and the release describes regulatory approvals and ongoing studies but does not replace individualized medical advice.
